This newsletter presents you the following key sessions:
1. Podcast with prof. dr. Bob Li about the CodeBreak 100 trial: phase II study of KRAS- G12C inhibition with
Sotorasib in non-small cell lung cancer (NSCLC)
2. No impact of adjuvant chemotherapy use on the benefit of adjuvant osimertinib in patients with resected
EGFR mutated NSCLC
3. Mobocertinib for previously treated EGFR exon 20 insertion mutant non-small cell lung cancer: updated
results of the phase I EXCLAIM trial
4. Gut microbiome composition correlates with chemotherapy response in advanced lung cancer
5. Neoadjuvant atezolizumab for early-stage NSCLC: encouraging results from the phase II LCMC3 trial
